Wedbush Decreases Earnings Estimates for Apogee Therapeutics

Apogee Therapeutics, Inc. (NASDAQ:APGE) – Stock analysts at Wedbush cut their Q3 2025 earnings per share estimates for Apogee Therapeutics in a report released on Monday, December 2nd. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.97) per share for the quarter, down from their prior estimate of ($0.95). Wedbush currently has a “Outperform” rating and a $90.00 target price on the stock. The consensus estimate for Apogee Therapeutics’ current full-year earnings is ($2.81) per share. Wedbush also issued estimates for Apogee Therapeutics’ FY2025 earnings at ($3.93) EPS, FY2026 earnings at ($4.06) EPS, FY2027 earnings at ($4.46) EPS and FY2028 earnings at ($5.93) EPS.

APGE has been the subject of several other research reports. Canaccord Genuity Group initiated coverage on shares of Apogee Therapeutics in a research note on Monday, November 25th. They issued a “buy” rating and a $89.00 price objective for the company. Guggenheim restated a “buy” rating and issued a $110.00 price target (up previously from $95.00) on shares of Apogee Therapeutics in a research note on Tuesday. Finally, Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 price objective on the stock. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $83.88.

Apogee Therapeutics Price Performance

NASDAQ APGE opened at $46.26 on Wednesday. The company has a market cap of $2.08 billion, a P/E ratio of -19.12 and a beta of 2.30. The stock has a 50-day moving average of $52.90 and a two-hundred day moving average of $48.30. Apogee Therapeutics has a 1-year low of $18.84 and a 1-year high of $72.29.

Hedge Funds Weigh In On Apogee Therapeutics

Several large investors have recently bought and sold shares of the stock. Wellington Management Group LLP boosted its holdings in shares of Apogee Therapeutics by 35.7% in the third quarter. Wellington Management Group LLP now owns 4,814,400 shares of the company’s stock valued at $282,798,000 after acquiring an additional 1,267,451 shares during the period. Driehaus Capital Management LLC boosted its stake in shares of Apogee Therapeutics by 2.6% during the second quarter. Driehaus Capital Management LLC now owns 2,117,870 shares of the company’s stock worth $83,338,000 after buying an additional 54,107 shares during the period. Perceptive Advisors LLC grew its stake in shares of Apogee Therapeutics by 2.2% in the 2nd quarter. Perceptive Advisors LLC now owns 2,105,636 shares of the company’s stock valued at $82,857,000 after purchasing an additional 45,241 shares during the last quarter. Affinity Asset Advisors LLC increased its holdings in shares of Apogee Therapeutics by 41.2% in the second quarter. Affinity Asset Advisors LLC now owns 836,283 shares of the company’s stock valued at $32,908,000 after purchasing an additional 244,190 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Apogee Therapeutics by 11.2% during the third quarter. Geode Capital Management LLC now owns 823,839 shares of the company’s stock worth $48,401,000 after purchasing an additional 82,978 shares during the last quarter. Institutional investors and hedge funds own 79.04% of the company’s stock.

Insider Transactions at Apogee Therapeutics

In related news, CEO Michael Thomas Henderson sold 40,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $56.23, for a total transaction of $2,249,200.00. Following the completion of the sale, the chief executive officer now owns 1,354,487 shares in the company, valued at $76,162,804.01. The trade was a 2.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Carl Dambkowski sold 6,665 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $59.12, for a total value of $394,034.80. Following the completion of the transaction, the insider now directly owns 267,463 shares of the company’s stock, valued at $15,812,412.56. This trade represents a 2.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 68,330 shares of company stock valued at $3,906,508. Insiders own 36.10% of the company’s stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.